If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> ONCOLOGY<br /> ISSN 2054-619X Vol 3.1 • March 2015 • emjreviews.com<br /> CONTENTS<br /> EDITORIAL BOARD................................................................................................................................. 4<br /> EDITOR’S PICK: PARADIGM SHIFT IN THE MANAGEMENT OF GYNAECOLOGICAL CANCERS 12<br /> • Katelijn Sap and Philippe Van Trappen<br /> FIELD CANCERISATION OF THE UPPER AERODIGESTIVE TRACT: SCREENING FOR SECOND<br /> PRIMARY CANCERS OF THE OESOPHAGUS IN CANCER SURVIVORS............................................. 21<br /> • Hans Scherübl et al.<br /> PERSPECTIVES IN SURGERY OF OLIGOMETASTATIC NON-SMALL-CELL LUNG CANCER......... 29<br /> • Fabio Villa et al.<br /> SYMPTOMS AND QUALITY OF LIFE IN GASTROENTEROPANCREATIC NEUROENDOCRINE<br /> TUMOURS.............................................................................................................<a title="EMJ Oncology 3.1 2015 page 1" href="http://viewer.zmags.com/publication/a09ab9b9?page=1"> ONCOLOGY ISSN 2054-619X </a> <a title="EMJ Oncology 3.1 2015 page 2" href="http://viewer.zmags.com/publication/a09ab9b9?page=2"> CONTENTS EDITORIAL BOARD.......................</a> <a title="EMJ Oncology 3.1 2015 page 3" href="http://viewer.zmags.com/publication/a09ab9b9?page=3"> ONCOLOGY DEVELOPMENT OF DRUGS TARGETING THE PI3</a> <a title="EMJ Oncology 3.1 2015 page 4" href="http://viewer.zmags.com/publication/a09ab9b9?page=4"> Editorial Board Editor-in-Chief: Prof Ahmad Aw</a> <a title="EMJ Oncology 3.1 2015 page 5" href="http://viewer.zmags.com/publication/a09ab9b9?page=5"> Oncology Prof Dr Jeff Lipton, Professor of M</a> <a title="EMJ Oncology 3.1 2015 page 6" href="http://viewer.zmags.com/publication/a09ab9b9?page=6"> European Medical Journal EMJ Oncology Vol 3.1 M</a> <a title="EMJ Oncology 3.1 2015 page 7" href="http://viewer.zmags.com/publication/a09ab9b9?page=7"> Welcome Hello, and a very warm welcome to this</a> <a title="EMJ Oncology 3.1 2015 page 8" href="http://viewer.zmags.com/publication/a09ab9b9?page=8"> Step up with GIOTRIF® (afatinib) to a new level o</a> <a title="EMJ Oncology 3.1 2015 page 9" href="http://viewer.zmags.com/publication/a09ab9b9?page=9"> Foreword Prof Ahmad Awada </a> <a title="EMJ Oncology 3.1 2015 page 10" href="http://viewer.zmags.com/publication/a09ab9b9?page=10"> SUBSCRIBE FREE TO OUR YOUTUBE CHANNEL www.youtube</a> <a title="EMJ Oncology 3.1 2015 page 11" href="http://viewer.zmags.com/publication/a09ab9b9?page=11"> Stu Rad Exclusive videos from the European So</a> <a title="EMJ Oncology 3.1 2015 page 12" href="http://viewer.zmags.com/publication/a09ab9b9?page=12"> EDITOR’S PICK My p</a> <a title="EMJ Oncology 3.1 2015 page 13" href="http://viewer.zmags.com/publication/a09ab9b9?page=13"> year in the United States. However, ovarian</a> <a title="EMJ Oncology 3.1 2015 page 14" href="http://viewer.zmags.com/publication/a09ab9b9?page=14"> ULTRA-RADICAL SURGERY FOR ADVANCED OVARIAN CANCER</a> <a title="EMJ Oncology 3.1 2015 page 15" href="http://viewer.zmags.com/publication/a09ab9b9?page=15"> laparoscopic procedures, the robotic approach</a> <a title="EMJ Oncology 3.1 2015 page 16" href="http://viewer.zmags.com/publication/a09ab9b9?page=16"> Deep injection into the cervix has a </a> <a title="EMJ Oncology 3.1 2015 page 17" href="http://viewer.zmags.com/publication/a09ab9b9?page=17"> targeted therapies partial response was seen in u</a> <a title="EMJ Oncology 3.1 2015 page 18" href="http://viewer.zmags.com/publication/a09ab9b9?page=18"> 21. Rutten MJ et al. Laparoscopy to predict the </a> <a title="EMJ Oncology 3.1 2015 page 19" href="http://viewer.zmags.com/publication/a09ab9b9?page=19"> Would you like to write for the EMJ blog? Intera</a> <a title="EMJ Oncology 3.1 2015 page 20" href="http://viewer.zmags.com/publication/a09ab9b9?page=20"> 18th ECCO - 40th ESMO E</a> <a title="EMJ Oncology 3.1 2015 page 21" href="http://viewer.zmags.com/publication/a09ab9b9?page=21"> FIELD CANCERISATION OF THE UPPER AERODIGESTIVE T</a> <a title="EMJ Oncology 3.1 2015 page 22" href="http://viewer.zmags.com/publication/a09ab9b9?page=22"> are increasing too; they are at increased risk of</a> <a title="EMJ Oncology 3.1 2015 page 23" href="http://viewer.zmags.com/publication/a09ab9b9?page=23"> compared with HPV-negative HNSCC.22 The r</a> <a title="EMJ Oncology 3.1 2015 page 24" href="http://viewer.zmags.com/publication/a09ab9b9?page=24"> ENDOSCOPIC SCREENING FOR EARLY OSCN The aim of s</a> <a title="EMJ Oncology 3.1 2015 page 25" href="http://viewer.zmags.com/publication/a09ab9b9?page=25"> preferred routine screening technique for second </a> <a title="EMJ Oncology 3.1 2015 page 26" href="http://viewer.zmags.com/publication/a09ab9b9?page=26"> A B C D E F Fig</a> <a title="EMJ Oncology 3.1 2015 page 27" href="http://viewer.zmags.com/publication/a09ab9b9?page=27"> Superficial HNCs OSCC patients have a risk</a> <a title="EMJ Oncology 3.1 2015 page 28" href="http://viewer.zmags.com/publication/a09ab9b9?page=28"> Wei Sheng Yan Jiu. 2012;41(5):723-9. 21. Curado M</a> <a title="EMJ Oncology 3.1 2015 page 29" href="http://viewer.zmags.com/publication/a09ab9b9?page=29"> PERSPECTIVES IN SURGERY OF OLIGOMETASTATIC </a> <a title="EMJ Oncology 3.1 2015 page 30" href="http://viewer.zmags.com/publication/a09ab9b9?page=30"> and grade, as well as the ‘seed and soil’ crossta</a> <a title="EMJ Oncology 3.1 2015 page 31" href="http://viewer.zmags.com/publication/a09ab9b9?page=31"> Stage 1 NSCLC with a solitary brain metastasis, c</a> <a title="EMJ Oncology 3.1 2015 page 32" href="http://viewer.zmags.com/publication/a09ab9b9?page=32"> of bleeding.28 Nevertheless, the monoclon</a> <a title="EMJ Oncology 3.1 2015 page 33" href="http://viewer.zmags.com/publication/a09ab9b9?page=33"> 1998-2004. 13. Albain KS et al. Survival determin</a> <a title="EMJ Oncology 3.1 2015 page 34" href="http://viewer.zmags.com/publication/a09ab9b9?page=34"> SYMPTOMS AND QUALITY OF LIFE IN GASTROENTERO</a> <a title="EMJ Oncology 3.1 2015 page 35" href="http://viewer.zmags.com/publication/a09ab9b9?page=35"> syndromes.3 Incidence in industrialised natio</a> <a title="EMJ Oncology 3.1 2015 page 36" href="http://viewer.zmags.com/publication/a09ab9b9?page=36"> iii) Insulinomas Insulinomas are rare neoplasm</a> <a title="EMJ Oncology 3.1 2015 page 37" href="http://viewer.zmags.com/publication/a09ab9b9?page=37"> will metastasise.22,23 They are most commonly fou</a> <a title="EMJ Oncology 3.1 2015 page 38" href="http://viewer.zmags.com/publication/a09ab9b9?page=38"> been overwhelmingly on medical therapies. A </a> <a title="EMJ Oncology 3.1 2015 page 39" href="http://viewer.zmags.com/publication/a09ab9b9?page=39"> REFERENCES 1. Ramage JK et al. Guidelines for th</a> <a title="EMJ Oncology 3.1 2015 page 40" href="http://viewer.zmags.com/publication/a09ab9b9?page=40"> 45. Vinik E et al. Development of the Norfolk qua</a> <a title="EMJ Oncology 3.1 2015 page 41" href="http://viewer.zmags.com/publication/a09ab9b9?page=41"> RECENT ADVANCES IN DEFINITIVE RADIOTHERAPY </a> <a title="EMJ Oncology 3.1 2015 page 42" href="http://viewer.zmags.com/publication/a09ab9b9?page=42"> for every EBRT fraction and reduction of safety m</a> <a title="EMJ Oncology 3.1 2015 page 43" href="http://viewer.zmags.com/publication/a09ab9b9?page=43"> DOSE ESCALATION Several randomised EBRT dose esc</a> <a title="EMJ Oncology 3.1 2015 page 44" href="http://viewer.zmags.com/publication/a09ab9b9?page=44"> randomised studies have shown an OS advantage for</a> <a title="EMJ Oncology 3.1 2015 page 45" href="http://viewer.zmags.com/publication/a09ab9b9?page=45"> Table 2: Randomised Phase III hypofractionation t</a> <a title="EMJ Oncology 3.1 2015 page 46" href="http://viewer.zmags.com/publication/a09ab9b9?page=46"> ABC Prostate PTV boost GTV PTV prostate Spac</a> <a title="EMJ Oncology 3.1 2015 page 47" href="http://viewer.zmags.com/publication/a09ab9b9?page=47"> future. The current standard implicates the deliv</a> <a title="EMJ Oncology 3.1 2015 page 48" href="http://viewer.zmags.com/publication/a09ab9b9?page=48"> 30. Pilepich MV et al. Phase III radiation therap</a> <a title="EMJ Oncology 3.1 2015 page 49" href="http://viewer.zmags.com/publication/a09ab9b9?page=49"> DEVELOPMENT OF DRUGS TARGETING THE PI3K SIGNALLIN</a> <a title="EMJ Oncology 3.1 2015 page 50" href="http://viewer.zmags.com/publication/a09ab9b9?page=50"> examples of targeted therapies include anti-</a> <a title="EMJ Oncology 3.1 2015 page 51" href="http://viewer.zmags.com/publication/a09ab9b9?page=51"> PI3K/Akt/mTOR Signalling in Leukaemia and Lymphom</a> <a title="EMJ Oncology 3.1 2015 page 52" href="http://viewer.zmags.com/publication/a09ab9b9?page=52"> antibody ofatumumab) (Table 1). BKM-120 is a pan-</a> <a title="EMJ Oncology 3.1 2015 page 53" href="http://viewer.zmags.com/publication/a09ab9b9?page=53"> CAL-101(idelalisib) BEZ-235 MK-2206 </a> <a title="EMJ Oncology 3.1 2015 page 54" href="http://viewer.zmags.com/publication/a09ab9b9?page=54"> Table 1: Overview of current clinical trials with</a> <a title="EMJ Oncology 3.1 2015 page 55" href="http://viewer.zmags.com/publication/a09ab9b9?page=55"> Table 1 continued. ID ClinicalTrials.gov Phas</a> <a title="EMJ Oncology 3.1 2015 page 56" href="http://viewer.zmags.com/publication/a09ab9b9?page=56"> These loops explain that synergy between selected</a> <a title="EMJ Oncology 3.1 2015 page 57" href="http://viewer.zmags.com/publication/a09ab9b9?page=57"> the PTEN/MMAC1 gene in non-Hodgkin’s lymphoma. </a> <a title="EMJ Oncology 3.1 2015 page 58" href="http://viewer.zmags.com/publication/a09ab9b9?page=58"> 64. Bartalucci N et al. Co-targeting Cell</a> <a title="EMJ Oncology 3.1 2015 page 59" href="http://viewer.zmags.com/publication/a09ab9b9?page=59"> ALLOIMMUNE THROMBOCYTOPAENIC DISORDERS: </a> <a title="EMJ Oncology 3.1 2015 page 60" href="http://viewer.zmags.com/publication/a09ab9b9?page=60"> platelet function: they serve as receptors </a> <a title="EMJ Oncology 3.1 2015 page 61" href="http://viewer.zmags.com/publication/a09ab9b9?page=61"> NAIT should be considered when </a> <a title="EMJ Oncology 3.1 2015 page 62" href="http://viewer.zmags.com/publication/a09ab9b9?page=62"> REFRACTORINESS TO PLATELET TRANSFUSIONS Platelet</a> <a title="EMJ Oncology 3.1 2015 page 63" href="http://viewer.zmags.com/publication/a09ab9b9?page=63"> transplantation, or an allogeneic bone marro</a> <a title="EMJ Oncology 3.1 2015 page 64" href="http://viewer.zmags.com/publication/a09ab9b9?page=64"> 26. Reik RA et al. Unique donor-suitability issue</a> <a title="EMJ Oncology 3.1 2015 page 65" href="http://viewer.zmags.com/publication/a09ab9b9?page=65"> MULTIPLE MYELOMA AND RENAL FAILURE *Patrizi</a> <a title="EMJ Oncology 3.1 2015 page 66" href="http://viewer.zmags.com/publication/a09ab9b9?page=66"> diabetic nephropathy or nephroangiosclerosi</a> <a title="EMJ Oncology 3.1 2015 page 67" href="http://viewer.zmags.com/publication/a09ab9b9?page=67"> light-chain deposition disease.6,33 A recent repo</a> <a title="EMJ Oncology 3.1 2015 page 68" href="http://viewer.zmags.com/publication/a09ab9b9?page=68"> appropriate dose reduction schedule as </a> <a title="EMJ Oncology 3.1 2015 page 69" href="http://viewer.zmags.com/publication/a09ab9b9?page=69"> 28. San Miguel JF et al. Bortezomib plus melphala</a> <a title="EMJ Oncology 3.1 2015 page 70" href="http://viewer.zmags.com/publication/a09ab9b9?page=70"> CHECKPOINT BLOCKADE IN CANCER IMMUNOTHERAPY: </a> <a title="EMJ Oncology 3.1 2015 page 71" href="http://viewer.zmags.com/publication/a09ab9b9?page=71"> and is kept in check by the immune system. The fin</a> <a title="EMJ Oncology 3.1 2015 page 72" href="http://viewer.zmags.com/publication/a09ab9b9?page=72"> There have been two mAbs to CTLA-4 which h</a> <a title="EMJ Oncology 3.1 2015 page 73" href="http://viewer.zmags.com/publication/a09ab9b9?page=73"> use of systemic steroids to treat immune-related </a> <a title="EMJ Oncology 3.1 2015 page 74" href="http://viewer.zmags.com/publication/a09ab9b9?page=74"> showed a significant association between PD-1</a> <a title="EMJ Oncology 3.1 2015 page 75" href="http://viewer.zmags.com/publication/a09ab9b9?page=75"> CONCLUSION In conclusion, immunomodulatory mAbs,</a> <a title="EMJ Oncology 3.1 2015 page 76" href="http://viewer.zmags.com/publication/a09ab9b9?page=76"> 2002;8(8):793-800. 29. Iwai Y et al. Involve</a> <a title="EMJ Oncology 3.1 2015 page 77" href="http://viewer.zmags.com/publication/a09ab9b9?page=77"> EUROPEAN MEDICAL JOURNAL provides influential arti</a> <a title="EMJ Oncology 3.1 2015 page 78" href="http://viewer.zmags.com/publication/a09ab9b9?page=78"> HOW I TREAT: PROGNOSTICATION IN CHRONIC LYMPHOCYT</a> <a title="EMJ Oncology 3.1 2015 page 79" href="http://viewer.zmags.com/publication/a09ab9b9?page=79"> No disease activity Prognostic Factors Clinic</a> <a title="EMJ Oncology 3.1 2015 page 80" href="http://viewer.zmags.com/publication/a09ab9b9?page=80"> or, in selected cases, allogeneic stem </a> <a title="EMJ Oncology 3.1 2015 page 81" href="http://viewer.zmags.com/publication/a09ab9b9?page=81"> SUBSCRIBE TO RECEIVE THE LATEST CATIONS PUBLI</a>